SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001171843-24-000297
Filing Date
2024-01-18
Accepted
2024-01-18 17:21:31
Documents
13
Period of Report
2024-01-16
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_011824.htm   iXBRL 8-K 24703
2 EXHIBIT 3.1 exh_31.htm EX-3.1 153108
  Complete submission text file 0001171843-24-000297.txt   384441

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bcrx-20240116.xsd EX-101.SCH 3030
4 XBRL LABEL FILE bcrx-20240116_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE bcrx-20240116_pre.xml EX-101.PRE 22369
7 EXTRACTED XBRL INSTANCE DOCUMENT f8k_011824_htm.xml XML 3395
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

IRS No.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 24542818
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)